|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, January 28, 2017 ) ReportsWeb.com has announced the addition of the “Progressive Supranuclear Palsy - Pipeline Review, H2 2016” The report outlines the evolution of enterprise content management, and identifies and assesses the best performing vendors in the market.
Summary
Pharmaceutical and Healthcare latest pipeline guide Progressive Supranuclear Palsy - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Progressive Supranuclear Palsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Progressive Supranuclear Palsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Progressive Supranuclear Palsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 6, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Progressive Supranuclear Palsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/progressive-supranuclear-palsy-pipeline-review-h2-2016
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Progressive Supranuclear Palsy (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Progressive Supranuclear Palsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Progressive Supranuclear Palsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Progressive Supranuclear Palsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Progressive Supranuclear Palsy (Central Nervous System)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Progressive Supranuclear Palsy (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Progressive Supranuclear Palsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001530746/sample
Few Points from Table of Content:
List of Tables 4
List of Figures 5
Introduction 6
Publisher Report Coverage 6
Progressive Supranuclear Palsy Overview 7
Therapeutics Development 8
Pipeline Products for Progressive Supranuclear Palsy - Overview 8
Pipeline Products for Progressive Supranuclear Palsy - Comparative Analysis 9
Progressive Supranuclear Palsy - Therapeutics under Development by Companies 10
Progressive Supranuclear Palsy - Therapeutics under Investigation by Universities/Institutes 11
Progressive Supranuclear Palsy - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Progressive Supranuclear Palsy - Products under Development by Companies 15
Progressive Supranuclear Palsy - Products under Investigation by Universities/Institutes 16
Progressive Supranuclear Palsy - Companies Involved in Therapeutics Development 17
AB Science SA 17
AbbVie Inc 18
AlzProtect SAS 19
Asceneuron SA 20
Bristol-Myers Squibb Company 21
Cortice Biosciences Inc 22
Intellect Neurosciences Inc 23
Prana Biotechnology Ltd 24
Sellas Inc 25
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001530746/buy/2000
Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
